786
Participants
Start Date
March 31, 2016
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2030
Epirubicin plus Cyclophosphamide
Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
Taxanes
Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
Taxanes plus Carboplatin
Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
Cancer Hospital Affiliated to Harbin Medical University, Harbin
Obstetrics & Gynecology Hospital of Fudan University, Shanghai
Shanghai JiaoTong University School of Medicine, Ruijin Hospital, Shanghai
Jiangsu Jiangyin People's Hospital, Jiangyin
The First People's Hospital of Wujiang District, Suzhou
Jiaxin Maternal and Child Health Care Hospital, Jiaxin
Lishui People's Hospital, Lishui
Shaoxing Shangyu People's Hospital, Shaoxing
Ningbo Medical Treatment Center Lihuili Hospital, Ningbo
Ningbo Women and Children's Hospital, Ningbo
Zhoushan Hospital, Zhoushan
Taizhou Central Hospital, Taizhou
Rui'an People's Hospital, Rui’an
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Guangdong Maternal and Child Health Care Hospital, Guangzhou
Foshan No.1 People's Hospital, Foshan
Fuding Hospital, Fuding
Quanzhou First Hospital, Quanzhou
Yancheng Hospital of TCM, Yancheng
Central Hospital of Huangpu District, Shanghai, Shanghai
Shanghai International Peace Maternal and child health care hospital, Shanghai
The Ninth People's Hospital of Shanghai, Shanghai
Hangzhou Cancer Hospital, Hangzhou
Zhejiang Provincial Hospital of TCM, Hangzhou
Ningbo First Hospital, Ningbo
Shaoxing No.2 Hospital, Shaoxing
Wenzhou People's Hospital, Wenzhou
Shanghai Jiao Tong University School of Medicine
OTHER